TABLE 1.

Prevalence of 23 antigens not routinely available by serologic testing^*

	Patients with SCD		Prevalence
Antigen	Positive	Negative	Patients with SCD	Blacks	Caucasian
hrB†	436	54‡	0.883	0.960	1.000
U	489§	5	0.990	0.990	0.999
Joa	491	3	0.994	0.990	1.000
Hy	493	1	0.998	0.990	1.000
V†	122	372	0.247	0.300	0.010
VS†	139	355	0.281	0.300	0.0001
Jsa†	82	412	0.166	0.200	0.0001
Jsb	492	2	0.996	0.990	1.000
k	494	0	1.000	1.000	0.998
Kpa	0	494	0.000	0.0001	0.020
Kpb	494	0	1.000	1.000	1.000
Lua∥	18	464	0.037	0.050	0.080
Lub∥	485	0	1.000	0.998	0.998
Dia∥	0	493	0.000	0.0001	0.0001
Dib∥	493	0	1.000	1.000	1.000
Coa	494	0	1.000	0.999	0.999
Cob†	8	486	0.016	0.100	0.100
Doa†	214	280	0.433	0.550	0.670
Dob†	460	34	0.931	0.890	0.820
LWa	494	0	1.000	1.000	1.000
LWb	0	494	0.000	NA	0.010
Sc1	494	0	1.000	0.990	0.990
Sc2	0	494	0.000	NA	0.010

^*Number of patients with SCD (n = 494) who genotyped positive or negative for each RBC antigen. Antigen prevalence among this cohort was compared to reported prevalence for blacks and Caucasians determined by serological typing in Reid et al.¹⁶ with the exception of hr^B (authors’ experience).

^†Antigens for which the frequency between Caucasians and patients with SCD had a p value of less than 0.0001.

^‡Does not include four individuals predicted to be hr^B– associated with DcE/DcE (R2R2).

^§Includes three U variants.

^∥No results were determined for 12 Lu^a, nine Lu^b, one Di^a, and one Di^b due to low signal intensity on the HEA BeadChip.

NA = not available.